HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 15 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Healthcare Weekly (Aug.18) - TCM Formula Granules VBP, Global Financing Rebound, CR Sanjiu

Sinopharm Group (1099.HK) 23H1 - Strong Growth Would Continue, but Profit Margin Is Under Pressure

Pre-IPO VISEN Pharmaceuticals - The Product Pipeline and the Key Risks

The Future Directions of A-Share After the Tumble and the Opportunities Behind

Pre-IPO WuXi XDC - The Beautiful Story and the Truth Behind

Moderna Inc (MRNA US) - What Would Happen After Moderna Enters China?

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Thematic (Sector/Industry)

Hong kong Healthcare equipment and services / Thematic (Sector/Industry)

<ul>
<li>It’s the first time in nearly thirty years for the State Council to directly issue <em>The Guidelines</em> giving specific instructions on attracting foreign investment. Therefore, it’s necessary to interpret the signals behind.</li>
<li>The core requirement is for foreign companies to bring their production capacity/core technology to China (e.g. Tesla, Moderna). The ultimate goal is to help China's industry upgrade, achieve technological breakthroughs.</li>
<li>However, the investment logic of "import substitution" naturally conflicts with attracting foreign investment and guarantee the “national treatment” of foreign-invested enterprises. So, investors may need to change thinking mode/strategies.</li>
</ul>


It’s the first time in nearly thirty years for the State Council to directly issue The Guidelines giving specific instructions on attracting foreign investment. Therefore, it’s necessary to interpret the signals behind.
The core requirement is for foreign companies to bring their production capacity/core technology to China (e.g. Tesla, Moderna). The ultimate goal is to help China's industry upgrade, achieve technological breakthroughs.
However, the investment logic of "import substitution" naturally conflicts with attracting foreign investment and guarantee the “national treatment” of foreign-invested enterprises. So, investors may need to change thinking mode/strategies.


China's Extremely Rare Policy to Attract Foreign Investment and the Signals Behind